## CTEP

Item No. 28773

CAS Registry No.: 871362-31-1
Formal Name: 2-chloro-4-[2-[2,5-dimethyl-1-
[4-(trifluoromethoxy)phenyl]-1H-imidazol-4-yl]ethynyl]-pyridine
MF: $\quad \mathrm{C}_{19} \mathrm{H}_{13} \mathrm{ClF}_{3} \mathrm{~N}_{3} \mathrm{O}$
FW: $\quad 391.8$
Purity:
UV/Vis.:
Supplied as: A solid
$\geq 98 \%$

Storage: $\quad-20^{\circ} \mathrm{C}$
Stability: $\quad \geq 4$ years


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures
CTEP is supplied as a solid. A stock solution may be made by dissolving the CTEP in the solvent of choice, which should be purged with an inert gas. CTEP is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CTEP in ethanol is approximately $25 \mathrm{mg} / \mathrm{ml}$ and approximately $30 \mathrm{mg} / \mathrm{ml}$ in DMSO and DMF.

CTEP is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CTEP should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. CTEP has a solubility of approximately $0.2 \mathrm{mg} / \mathrm{ml}$ in a 1:4 solution of DMSO:PBS ( pH 7.2 ) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

CTEP is an inverse agonist of metabotropic glutamate receptor 5 (mGluR5, $\mathrm{K}_{\mathrm{i}} \mathrm{s}=16.4,12.6$, and 9.5 nM for the human, rat, and mouse receptors, respectively, in a radioligand binding assay). ${ }^{1}$ It is selective for mGluR5 over mGluR1, $-2,-3,-4,-6,-7$, and $-8\left(\mathrm{IC}_{50} \mathrm{~s}=>10 \mu \mathrm{M}\right.$ for all) and the histamine $\mathrm{H}_{1}$ and $\mathrm{a}_{5} \beta_{3} \gamma_{2}$ subunit-containing $\mathrm{GABA}_{\mathrm{A}}$ receptors ( $\mathrm{K}_{\mathrm{i}} \mathrm{s}=>4$ and $>3.2 \mu \mathrm{M}$, respectively), but does inhibit adenosine $\mathrm{A}_{1}, \mathrm{~A}_{3}$, muscarinic, and kainate receptors ( $\mathrm{K}_{\mathrm{i}} \mathrm{s}=6.2,2.3,5.3$, and $7.9 \mu \mathrm{M}$, respectively), as well as L-type calcium and sodium channels ( $\mathrm{K}_{\mathrm{i}} \mathrm{s}=2.7$ and $5 \mu \mathrm{M}$, respectively) in a panel of 103 receptors, enzymes, and ion channels at $10 \mu \mathrm{M}$. CTEP inhibits inositol phosphate accumulation and quisqualate-induced calcium mobilization in HEK293 cells expressing human recombinant mGluR5 ( $\mathrm{IC}_{50} \mathrm{~s}=6.4$ and 11.4 nM , respectively). It reduces stress-induced hyperthermia in mice and increases drinking in the Vogel conflict test in rats, indicating anxiolytic-like activity, when administered at a dose of $0.3 \mathrm{mg} / \mathrm{kg}$.

## Reference

1. Lindemann, L., Jaeschke, G., Michalon, A., et al. CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J. Pharmacol. Exp. Ther. 339(2), 474-486 (2011).
[^0]
[^0]:    WARNING
    THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

    ## SAFETY DATA

    This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

